Episode Details
Back to Episodes
The ABCs of ADCs: Why antibody-drug conjugates are so hot right now
Published 2 years, 4 months ago
Description
These days you can hardly move without figuratively bumping into antibody-drug conjugates (ADCs). This week we discuss Pfizer's strategic priorities for oncology - focused on ADCs and less on small molecules - and how the market is being influenced by the IRA.